Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is exhibiting at the 2023 Consumer Electronics Show in Las Vegas from January 5-8.

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is exhibiting at the 2023 Consumer Electronics Show in Las Vegas from January 5-8. The company will showcase its Co-Dx PCR at-home and point-of-care platform, which is undergoing clinical evaluations prior to FDA submission. Interested attendees can visit Booth #8063 in the North Hall. The Co-Dx PCR platform is currently not for sale and is pending FDA review. Co-Diagnostics specializes in molecular diagnostics technology, focusing on nucleic acid detection for various applications.

Argus Session date unavailable

-2.30% session move Open Argus

Details

News Market Reaction – CODX

The recorded move for CODX in the trading session of this news was -2.30%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the 2023 Consumer Electronics Show (CES) this year from January 5-8 in Las Vegas, Nevada.

The Company will be exhibiting its upcoming Co-Dx PCR at-home and point-of-care platform, currently in the final stages of preparation for clinical evaluations prior to submission to the U.S. Food and Drug Administration for regulatory authorization. Attendees interested in learning more about the Company and its products are invited to visit Booth #8063 in the North Hall of the Las Vegas Convention Center.

The Co-Dx PCR platform is subject to FDA review and is not currently for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-ces-2023-january-5-8-301714315.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Co-Diagnostics, Inc. presenting at CES 2023?

Co-Diagnostics is showcasing its Co-Dx PCR at-home and point-of-care platform.

When is Co-Diagnostics hosting its booth at CES 2023?

Co-Diagnostics will host its booth at CES from January 5-8, 2023.

Where can I find Co-Diagnostics at CES 2023?

You can visit Co-Diagnostics at Booth #8063 in the North Hall of the Las Vegas Convention Center.

Is the Co-Dx PCR platform for sale?

No, the Co-Dx PCR platform is not currently for sale and is subject to FDA review.

When will Co-Diagnostics submit the Co-Dx PCR platform for FDA approval?

The Co-Dx PCR platform is in the final stages of preparation for clinical evaluations prior to FDA submission.